A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients

Trial Profile

A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs MK 1075 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 08 Sep 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 a per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top